Kornimate/medical-research-clean huggingface dataset:
bicycle ergometer training in duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy

Summary: the progressive muscle weakness and contractures of the patients adversely affect their gait and balance. it is known that the disorder of the patients' balance and gait affects their functional capacity. the aim of this study is to examine the effects of bicycle ergometer training on gait and balance in children with duchenne muscular dystrophy. twenty-four children with dmd included in the study will be divided into two groups as home program and home program+bicycle ergometer training with block randomization method. home program including stretching, respiratory, range of motion, posture and mild resistance exercise with body weight will be asked to apply 3-5 days a week for 12 weeks, aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 40 minutes total duration consisting of 5 min warm up and 5 min cool down period. gait and balance were evaluated with gaitrite and bertec balance check screener, successively. assessments will be applied at pre-training and after 12 weeks of training.


Eligibility criteria:
inclusion criteria: * children have diagnosis of dmd confirmed by genetic analysis, * children can walk with unsupported. exclusion criteria: * children have undergone any surgery or suffered injury of the lower limbs, * children have severe contractures of lower limbs, * children have low cooperation * children have comorbid disease, * children were applied regular aerobic training such as bicycle training and hydrotherapy in last 6 months.

Keywords: duchenne muscular dystrophy bicycle training gait balance
liposomal doxorubicin, vincristine, & dexamethasone plus arsenic trioxide in untreated symptomatic multiple myeloma

Conditions: Multiple Myeloma

Summary: this study will assess the ability of doxorubicin, vincristine and dexamethasone plus arsenic trioxide to achieve an overall response rate of greater than 60%.

rationale: the chemotherapy combination of doxorubicin, vincristine and dexamethasone (dvd) has been used with some efficacy in patients with multiple myeloma. however, dvd's efficacy is primarily considered palliative for patients with this condition. the current study adds arsenic trioxide to the dvd combo to assess if all of the treatments together improve patient outcomes. previous studies suggest that arsenic trioxide may enhance the efficacy of specific chemotherapy agents including those in dvd; however, research in people has not yet demonstrated this improved effectiveness. because the safety of arsenic trioxide has been tested in this patient population, this phase ii study will gather more information about safety and also measure efficacy through various measures. purpose: this study will evaluate the safety and efficacy of doxorubicin, vincristine and dexamethasone plus arsenic trioxide in untreated patients with symptomatic multiple myeloma. the biology of the tumor and other molecular changes will also be assessed in patients through collections of blood and marrow samples. treatment: patients in this study will receive arsenic trioxide, doxorubicin, vincristine and dexamethasone. during the first five days of the study, patients will be given arsenic trioxide each day through an intravenous infusion. no treatments will be provided on days six and seven. after this first week, patients will then receive study drugs on the following schedule every four weeks: doxorubicin and vincristine on day one, dexamethasone on days one through four, and arsenic trioxide twice each week. this schedule can be repeated up to four times for a total of approximately four months. several tests and exams will be given throughout the study to closely monitor patients. supportive care will be provided to help regulate side effects from study drugs and maintain quality of life in patients. treatments will be discontinued due to disease growth or unacceptable side effects.

Eligibility criteria:
inclusion criteria: * must have multiple myeloma * no prior chemotherapy, thalidomide, or corticosteroids treatments for multiple myeloma * ecog performance status must be 0-2 exclusion criteria: * resting left ventricular cardiac ejection fraction ≥50% by echo or muga scan. * qt interval ≥480 msec on baseline ecg. * no history of cardiac disease. * pregnant or breast-feeding. * no history of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hcl or the components of doxil. * history of prior or concurrent malignancy or myelodysplasia.

Keywords: untreated patients symptomatic
erector spinae plane block analgesia for lumbar spine fusion surgery

Conditions: Pain, Postoperative

Summary: the purpose of this study was to investigate the effect of a bilateral ultrasound guided erector spinae plane block on the pain scores and opoid utiliziation in fusion surgery of the lumbar spine.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists class i-iii adult patients * bmi less than or equal 35 kg/m2 exclusion criteria: * patient refusal * unable to give consent * age \ 65 * bmi more than 35 kg/m2 * known allergy to the study medication * coagulopathies or on anticoagulant medications * hepatic insufficiency * renal insufficiency * chronic opioid use
the prevalence of dysfunctional breathing in children and adolescents with asthma

Conditions: Dysfunctional Breathing; Asthma in Children; Asthma

Summary: the purpose of the study is to investigate the prevalence of dysfunctional breathing in children and adolescents with asthma in a hospital outpatient clinic. participants are invited to take the nijmegen questionnaire and the asthma control questionnaire. the prevalence of dysfunctional breathing defined as nq score \>= 23 is calculated, and demographics are compared between children with and without dysfunctional breathing.

the purpose of the study is to investigate the prevalence of dysfunctional breathing in children and adolecents with asthma in a hospital outpatient clinic. participants are invited to take the nijmegen questionnaire and the asthma control questionnaire, during appointments at the outpatient clinic. for this study purpose, each participant only takes the questionnairres once. patient data regarding age, sex, asthma medication, lung function, allergic sensitization, method of asthma diagnose, height, weight and body mass index is registered from the electronical patient journal. the prevalence of dysfunctional breathing in the cohort is calculated as the fraction of children with a nq score \>= 23. the group of children and adolescents with dysfunctional breathing is characterized and compared to the group without dysfunctional breathing, regarding the descriptives mentioned above.

Eligibility criteria:
inclusion criteria: * asthma diagnosed by lung function tests and/or typical symptoms. * treatment with inhaled corticosteroids in minimum 3 months. exclusion criteria: • other significant cardiopulmonary or muscoluskeletal conditions.

Keywords: dysfunctional breathing asthma in children asthma in adolescents
anti-inflammatory type ii monocyte induction by glatiramer acetate (copaxone) treatment of multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to determine whether glatiramer acetate (copaxone) will induce anti-inflammatory type ii monocyte development during treatment of ms, and if these antigen presenting cells (apc) will promote th2 and treg differentiation of naïve t cells.


Eligibility criteria:
inclusion criteria: * relapsing-remitting (rr) ms patients (mcdonald criteria) * ages 18-55 * males and females * edss score ≤5 * no prior treatment with copaxone * prior treatment with corticosteroids or interferon-beta (-1a or -1b) is acceptable, provided there is a washout period of at least one month exclusion criteria: * treatment with tysabri, novantrone or cyclophosphamide * treatment with other immunomodulatory therapies (e.g. imuran, mycophenolate or methotrexate) * primary-progressive (pp) and secondary-progressive (sp) multiple sclerosis * pregnancy

Keywords: relapsing-remitting multiple sclerosis copaxone glatiramer acetate ms
pain control after arthroscopic shoulder surgeries

Conditions: Post Operative Pain

Summary: this study will be conducted to compare the perioperative analgesic efficacy of ultrasound - guided interscalene brachial plexus block versus combined shoulder anterior capsular block and anterior suprascapular nerve block for arthroscopic shoulder surgeries.


Eligibility criteria:
inclusion criteria: * patients aged 20-65 years of both sexes, with american society of anesthesiologists (asa) physical status i or ii admitted for arthroscopic shoulder surgery. exclusion criteria: * patient refusal. * uncooperative patient. * patient with neurological deficit. * patients with respiratory disorders. * patient with bleeding disorders. * infection at the block injection site. * patients with history of allergy to local anesthetics.
evaluation of antibiotherapy prescribed for outpatients from emergency departments

Conditions: Infectious Disease; Emergencies

Summary: french health insurance data indicate that approximately 15% of ambulatory antibiotic consumption is generated by hospital prescriptions. this extra-hospital consumption represents a greater volume than intra-hospital consumption. to date, hospital indicators of good antibiotic use do not include this outpatient dimension. this study will provide a snapshot of the proportion of ambulatory antibiotics generated by emergencies and analyze compliance with management recommendations.this study will serve as a basis for developing indicators of outpatient antibiotic consumption generated by hospital activity and for identifying specific intervention targets aimed at the misuse situations that have been highlighted. this study will be carried out in the form of a repeated survey on a given day (4 days, one across each season), carried out by the local mobile antibiotic therapy team, using a standardized grid. the survey will concern all the medical records of the patients visiting any emergency department on the days of the survey. the evaluation of antibiotic therapies prescribed in discharge orders will be carried out in accordance with local management recommendations by the site investigator (infectious disease and/or emergency medicine specialist), who will assess whether the prescription is in accordance with the recommendations or not.


Eligibility criteria:
inclusion criteria: * visit on emergency department on one of the survey days * age ≥18 exclusion criteria: * patient opposed to the collection of his/her data * patient under guardianship or curatorship
a pilot efficacy and safety study of st101 in essential tremor

Conditions: Essential Tremor

Summary: this study will look at the ability of st101 to treat symptoms in subjects with essential tremor. this study will also examine the safety and tolerability of the drug. this study is evaluating one dose level of st101 versus placebo in a cross-over fashion. this means that all patients will receive both st101 and placebo, but they will receive it in a random (by chance) order.

essential tremor (et) is a slowly progressive, chronic neurological disorder characterized by a 4- to 12-hertz tremor, which can involve the arms, head, voice and lower extremities. although the hallmark of the disorder is thought to be the kinetic tremor, et patients usually also manifest a postural tremor as well. kinetic tremor (tremor with voluntary movements) may interfere with fine motor skills (e.g., writing, eating, drinking from a cup, pouring liquids); and depending upon its severity, may result in significant disability and diminished quality of daily living. essential tremor represents an area of unmet medical need and this study is designed as a safety, tolerability and proof-of-concept investigation of the ability of st101 to improve tremor. in this 2-stage study, subjects will be randomly assigned to either st101 or placebo in stage 1, and will receive the alternate treatment in stage 2.

Eligibility criteria:
inclusion criteria: * diagnosis of definite or probable essential tremor (et) as defined by the tremor investigational group with involvement of the hands and arms of at least 2 years duration * tremor severity score of \>/= 2 in at least one upper extremity on the fahn-tolosa-marin tremor rating scale * subject who is accessible by telephone * subject who can comply with study visits, study drug compliance, and study procedures. exclusion criteria: * subject whose tremor is adequately controlled on a current treatment * subject who is pregnant, plans to become pregnant during the study or within 2 months of completing the study or who is presently lactating or breast-feeding * subject with other medical conditions that may cause or explain subject's tremor * subject with a recent history of hematologic/oncologic disorders * subject taking medication(s) that might produce tremor or interfere with the evaluation of tremor * subject who has had surgical intervention for their tremor in the past (e.g., ablative thalamotomy or gamma knife thalamotomy), or has had a botulinum toxin injection in the 6 months prior to screening

Keywords: tremor whiget fahn tolosa marin scale
statins role in acute ischemic stroke

Conditions: Stroke, Acute

Summary: strokes is amajor cause of death and disabilities in different countried

stroke is a major cause of mortality and disability in modern societies. statins are effective medications in decreasing cardiovascular events through lipid lowering and pleiotropic effects. ischemic stroke is burdened with a high morbidity and mortality in our society. however, there are few effective and largely available therapies for this devastating disease. in additon to advancing acute reperfusion therapies, there is a need to develop treatments aimed to promote repair and regeneration of brain tissue damaged by ischemia (neurorecovery)(1,2,3). therapeutic angiogenesis and vasculogenesis represent novel approaches of regenerative medicine that may help in the cure of patients with acute ischemic stroke. translation of our knowledge about these processes from the bench to bedside is still underway. although angiogenesis (the sprouting of new blood vessels from pre-existing vascular structures) is likely to contribute to neurorepair, the finality of the angiogenic response in acute ischemic stroke has not been fully elucidated. the first therapeutic approach to angiogenesis after ischemic stroke would be the modulation of the endogenous angiogenic response. in this setting, early instauration of physical activity, statins, and peroxisome proliferator-activated receptor-γ agonists may enhance angiogenesis and neuroregeneration statins have been shown to improve the functional outcome of patients after an ischemic stroke. we hypothesized that daily statin intake improves functional outcome after an acute ischemic stroke (4,5,6,7,8) duplex sonography is the best noninvasive modality for investigation of possible carotid artery stenosis to evaluate the intema media thickness of carotid artery in patients of acute ischemic stroke before and after receiving high dose of statins to evaluate its effectiveness in management and appropriate dose of statins (9.10.11.12,13,14)

Eligibility criteria:
inclusion criteria: * .patients.have acute ischemic stroke within 24 hours of onset. 2.patient not received intravenous thrombolysis or mechanical thrombectomy3.patients with no contraindications or hypersensitivity to statins exclusion criteria: * 1. patient received iv thrombolysis or underwent mechanical thrombectomy 2. patient have acute ischemic stroke with onset of more than 24 hours 3.patients have hypersestivty or contraindication to statin 4:patients refuse to participate in the study
post marketing surveillance study to observe safety and efficacy of sutene

Conditions: Gastrointestinal Stromal Tumors

Summary: to monitor use in real practice including adverse events and efficacy on sutent capsules (sunitinib malate)

all the patients prescribed according to approved indications at contracted institutions

Eligibility criteria:
inclusion criteria: * patients diagnosed as gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate, or advanced renal cell carcinoma (arcc) will be included in the study, or patients diagnosed as unresectable, well-differentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma. exclusion criteria: * any patient who does not agree that pfizer and companies working with pfizer use his/her information will be excluded. * patients with hypersensitivity to sunitinib malate or to any other component of sutent

Keywords: sutene post-marketing surveillance gist rcc korea
evolution and risk factors associated with geographic atrophy progression

Conditions: Geographic Atrophy

Summary: age-related macular degeneration is one of the leading causes of blindness worldwide. the factors that induce the progression of geographic atrophy, the advanced form of dry age-related macular degeneration, remain poorly understood. the aims of this study are to describe the natural history of geographic atrophy and identify potential risk factors associated with a faster spread of atrophy that may be used to develop rational therapies.

age-related macular degeneration is the leading cause of blindness in developed countries. geographic atrophy is the advanced form of dry age-related macular degeneration, and currently has no effective therapy. little is known about the risk factors that drive the progression of geographic atrophy, and yet they are crucial to understand the mechanisms of the disease. therefore, the identification of risk factors associated with a faster spread of atrophy may help contribute to identify the causes of the disease and, ultimately, to develop new therapeutic strategies to manage the disorder. the current prospective, observational, natural history study has the following objectives: * describe the natural history of geographic atrophy in anatomic and visual terms * identify risk factors associated with a faster enlargement of atrophy the main hypothesis is that lipofuscin accumulation at the borders of atrophy as seen with fundus autofluorescence imaging is associated with a faster progression of the disease.

Eligibility criteria:
inclusion criteria: * both sexes * 50 years of age or older * uni or bilateral areas of geographic atrophy in the macula (as defined as areas devoid of retinal pigment epithelium measuring at least 0.5 disk areas on a 35º fundus photograph centered on field 2) secondary to age-related macular degeneration * willing to provide informed consent exclusion criteria: * other causes of geographic atrophy aside from age-related macular degeneration (ie, drug induced, central serous chorioretinopathy) * prior history of wet age-related macular degeneration * other significant concomitant macular diseases (ie, significant epiretinal membrane, stage ii-iv macular hole) * previous treatment with macular laser photocoagulation, photodynamic therapy, antiangiogenic drugs or other treatments for wet age-related macular degeneration * intraocular surgery aside from phacoemulsification * inability to measure the full extent of the area of atrophy on a 35º fundus autofluorescence image centered on field 2 * areas of geographic atrophy in direct contact with peripapillary areas of atrophy

Keywords: geographic atrophy, prognosis, risk factors, natural history
a study to assess new participant's perspectives beyond clinical efficacy of monoclonal antibody-based relapsing remitting multiple sclerosis (rrms) treatments

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: the primary objective of the study is to understand what the added value of natalizumab (tysabri®) treatment is from a participant's perspective at a given time, based on a one-shot survey. the secondary objectives of the study also aim to characterize the participant's decision-making process to get the treatment; the burden of treatment, characterization of the study population, assessment of the quality of life (qol), and fatigue dimension.


Eligibility criteria:
inclusion criteria: • participants diagnosed with rrms and followed by a neurologist in france. exclusion criteria: • lack of literacy note: other protocol-defined inclusion/exclusion criteria may apply.
patient profiling and outcome assessment in spinal cord stimulation for chronic back and/or leg pain

Conditions: Failed Back Surgery Syndrome; Chronic Pain

Summary: the prostim study is an ongoing prospective, multicentric and observational clinical study. patients are recruited in three different centers in eastern belgium from may 2018 onwards. this real-world data collection approaches the outcome assessment of daily medical practice. a hierarchical cluster analysis is used to identify significant patient clusters based on the visual analogue scale (vas), oswestry disability index (odi), pain vigilance and awareness questionnaire (pvaq), pain catastrophizing scale (pcs) and euroqol with five dimensions for health-related quality of life (eq-5d). patient clusters will be assessed on the change in biopsychosocial variables after six weeks, three and twelve months. secondary outcomes include the comparison of pain medication use, scs parameters, treatment satisfaction and return to work.


Eligibility criteria:
inclusion criteria: * male/female over 18 years old. * chronic intractable back and/or leg pain (psps t2), refractory to conservative treatment measures. * positive recommendation after multidisciplinary assessment including psychiatric assessment. * patients are capable of giving written informed consent. exclusion criteria: * negative recommendation after multidisciplinary assessment (ex. psychiatric disorders). * insufficient improvement during trial period. * previous scs implantation. * removal due to complication (infection, loss of function,...) * surgical contraindication (infection of surgical site, coagulation disorders,..) * pregnancy.

Keywords: spinal cord stimulation patient profiling treatment pathways outcome assessment medial pathway lateral pathway descending pain modulation